Literature DB >> 18081153

Molecular profiling and risk stratification of adenocarcinoma of the colon.

Matthew G Mutch1.   

Abstract

Staging systems are used to predict the clinical and biologic behavior of tumors. This manuscript examines several molecular markers that hope to improve staging for colon cancer. It is unclear if a molecular marker, genetic signature, or a combination of histologic, genetic, and molecular parameters will provide the best prognostic information. What is clear is that more accurate staging tools are needed so patients receive the best therapy. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081153     DOI: 10.1002/jso.20915

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  26 in total

1.  High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.

Authors:  Karina Bauer; Ulrich Nitsche; Julia Slotta-Huspenina; Enken Drecoll; Claus Hann von Weyhern; Robert Rosenberg; Heinz Höfler; Rupert Langer
Journal:  Cell Oncol (Dordr)       Date:  2012-04-26       Impact factor: 6.730

2.  MCM2 and MCM5 as prognostic markers in colon cancer: a worthwhile approach.

Authors:  Maximilian Burger
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

3.  Natural products and colon cancer: current status and future prospects.

Authors:  Subapriya Rajamanickam; Rajesh Agarwal
Journal:  Drug Dev Res       Date:  2008-11-01       Impact factor: 4.360

Review 4.  Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition.

Authors:  Manny D Bacolod; Francis Barany
Journal:  Ann Surg Oncol       Date:  2011-02-24       Impact factor: 5.344

5.  Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.

Authors:  Aikaterini Tsouma; Chrysanthi Aggeli; Panagiotis Lembessis; George-N Zografos; Dimitris-P Korkolis; Dimitrios Pectasides; Maria Skondra; Nikolaos Pissimissis; Anastasia Tzonou; Michael Koutsilieris
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 6.  Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.

Authors:  Lorenzo F Sempere
Journal:  Expert Rev Mol Diagn       Date:  2011-11       Impact factor: 5.225

7.  Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer.

Authors:  Josep Martí; Josep Fuster; Anna M Solà; Georgina Hotter; Rafael Molina; Amalia Pelegrina; Joana Ferrer; Ramon Deulofeu; Constantino Fondevila; Juan Carlos García-Valdecasas
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

Review 8.  MicroRNAome genome: a treasure for cancer diagnosis and therapy.

Authors:  Ioana Berindan-Neagoe; Paloma del C Monroig; Barbara Pasculli; George A Calin
Journal:  CA Cancer J Clin       Date:  2014-08-07       Impact factor: 508.702

9.  Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: a pilot prospective study.

Authors:  J Martí; J Fuster; J M Estanyol; F Fernández; R Deulofeu; J Ferrer; A Pelegrina; A Reyes; C Fondevila; J C García-Valdecasas
Journal:  Clin Transl Oncol       Date:  2013-01-30       Impact factor: 3.405

10.  Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy.

Authors:  Feng Zhu; Jing Ma; Dongdong Ru; Ningning Wu; Yunhua Zhang; Huiyuan Li; Xiaoli Liu; Jianfeng Li; Huiling Zhang; Yue Xu; Jiangman Zhao; Hui Tang; Yusheng Wang; Weihua Fu
Journal:  J Oncol       Date:  2021-05-26       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.